WHO ICTRP trial
Dose-Dense ABVD Study: An accelerated delivery of Adriamycin, Bleomycin…
ACTRN12612000137897 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12612000137897 |
|---|---|
| Public title | Dose-Dense ABVD Study: An accelerated delivery of Adriamycin, Bleomycin, Vinblastin and Dacarbazine for patients with Hodgkin Lymphoma |
| Scientific title | A Phase II Single Arm Study Assessing The Feasibility And Toxicity Of Dose-Dense ABVD In Patients With Early Stage Unfavourable And Advanced Stage Hodgkin Lymphoma. |
| Primary sponsor | Queensland Health |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | Australia |
| Conditions | Early Stage Unfavourable Hodgkin Lymphoma;Advanced Stage Hodgkin Lymphoma; Early Stage Unfavourable Hodgkin Lymphoma Advanced Stage Hodgkin Lymphoma;Cancer - Hodgkin's |
| Interventions | For early stage unfavourable disease: 4 cycles of ABVD plus 30.6Gy IF-XRT (extended field radiation therapy) Adriamycin at 25mg/m2 intravenous on day 1 and 12 of a 21 day cycle Bleomycin at 10,000 IU/m2 intravenous on day 1 and 12 of a 21… |
| Registration date | Jan 2, 2012 |
| Target size | 31 |
| Secondary IDs | Nil |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: